Skip to Main Content

Paper Details

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
Clin Cancer Res
38
2022
-TACC3 fusion, -TACC3 fusions, BGJ398, FGFR, FGFR1, FGFR1-3, FGFR3, Gliomas, Hyperphosphatemia, Infigratinib, Patients, TACC3, gliomas, infigratinib, patients, tumors
Author NameAffiliation
Timothy F CloughesyUniversity of California at Los Angeles
Timothy F CloughesyUniversity of California at Los Angeles
Vinay K PuduvalliOhio State University Wexner Medical Center
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute
Nicholas ButowskiUniversity of California San Francisco
Nicholas ButowskiUniversity of California San Francisco
Morris D Groves
  • 1 - 7

Datasets

Release 1.2